Q5128 is the HCPCS code for: Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg. In 2024, 470 providers billed Q5128 937,303 times, an estimated $169.3M paid by Medicare.
Q5128 is a Part B drug code: Medicare pays an ASP-based rate of $82.53 per 0.1 mg (2026 Q3 ASP drug pricing file). Total payment per patient depends on the dose billed.
A billed "service" on this code is one 0.1 mg unit, not one patient visit. That's why the service counts below run high.
What Medicare actually paid per service in 2024, on average: $180.63 (observed payment across all settings and modifiers, not a fee-schedule rate).
The top 5 billers nationally, ranked by 2024 Medicare service volume.
| # | Provider | Specialty | Location | Services | Est. Medicare paid |
|---|---|---|---|---|---|
| 1 | Omesh Gupta, MD | Ophthalmology | Plymouth Meeting, PA | 18,534 | $3.3M |
| 2 | Richard Kaiser, MD | Ophthalmology | Plymouth Meeting, PA | 18,370 | $3.3M |
| 3 | Mitchell Fineman, MD | Ophthalmology | Plymouth Meeting, PA | 13,985 | $2.5M |
| 4 | Marc Spirn, MD | Ophthalmology | Plymouth Meeting, PA | 13,036 | $2.4M |
| 5 | James Vander, MD | Ophthalmology | Plymouth Meeting, PA | 12,932 | $2.3M |
Prospect 811 answers "what is this code, what does it pay, and who bills it?" for every billable code, then filters the answer to your exact territory, with phone numbers. $79/month, no contract, 14-day refund.
Start prospecting →